Differential Effect of Initiating Moderate Red Wine Consumption on 24-h Blood Pressure by Alcohol Dehydrogenase Genotypes: Randomized Trial in Type 2 Diabetes

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41292483

Terms of Use
This article was downloaded from Harvard University’s DASH repository, WARNING: This file should NOT have been available for downloading from Harvard University’s DASH repository.
Differential Effect of Initiating Moderate Red Wine Consumption on 24-h Blood Pressure by Alcohol Dehydrogenase Genotypes: Randomized Trial in Type 2 Diabetes

Yftach Gepner,1* Yaakov Henkin,2* Dan Schwarzfuchs,3 Rachel Golan,1 Ronen Durst,4 Ilan Shelef,2 Ilana Harman-Boehm,2 Shosana Spitzen,4 Shula Witkow,1 Lena Novack,1 Michael Friger,1 Osnat Tangi-Rosental,1 Dana Sefarty,1 Nitzan Brit,1 Michal Rein,1 Noa Cohen,1 Yoash Chassidim,2 Benny Sarusi,3 Talia Wolak,2 Meir J. Stampfer,5 Assaf Rudich,1 and Iris Shai1

AIMS Observational studies report inconsistent associations between moderate alcohol intake and blood pressure (BP). In a sub-study of a larger randomized controlled trial, we assessed the effect of initiating moderate red wine consumption on 24-h BP recordings and the effect of a common genetic variant of alcohol dehydrogenases (ADH) among patients with type 2 diabetes.

METHODS Fifty-four type 2 diabetes, alcohol abstainers were randomized to consume 150 ml/dinner dry red wine or mineral water. Both groups were guided to adhere to a Mediterranean diet, without caloric restriction. We measured 24-h ambulatory BP monitoring (ABPM) at baseline and after 6 months.

RESULTS Participants (age = 57 years; 85% men; mean 24-h BP = 129/77 mm Hg) had 92% 6-month retention. After 6 months of intervention, the average 24-h BP did not differ between the wine and water groups. A transient decrease in BP was observed in the red wine group at midnight (3–4 hours after wine intake: systolic BP: red wine = −10.6 mm Hg vs. mineral water: +5.6 mm Hg; P = 0.014). In a second post hoc sub-analysis among the red wine consumers, individuals who were homozygous for the gene encoding ADH1B*2 variant (Arg48His; rs1229984, TT, fast ethanol metabolizers) exhibited a reduction in mean 24-h systolic BP (−8.0 mm Hg vs. +3.7 mm Hg; P = 0.002) and pulse pressure (−3.8 mm Hg vs. +1.2 mm Hg; P = 0.032) compared to heterozygotes and those homozygous for the ADH1B*1 variant (CC, slow metabolizers).

CONCLUSIONS Initiating moderate red wine consumption at dinner among type 2 diabetes patients does not have a discernable effect on mean 24-h BP. Yet, a modest temporal BP reduction could be documented, and a more pronounced BP-lowering effect is suggested among fast ethanol metabolizers.

CLINICAL TRIALS REGISTRATION ClinicalTrials.gov Identifier: NCT00784433.

Keywords: ambulatory measurement; blood pressure; hypertension; moderate alcohol; pulse pressure; randomized controlled trial; type 2 diabetes.

doi:10.1093/ajh/hpv126

Elevated blood pressure (BP) is prevalent in about one-quarter of adults in industrialized countries and contributes to considerable morbidity and mortality attributed to stroke, renal failure, heart failure, and coronary heart disease.1 Observational studies suggest an association between moderate alcohol intake and reduced cardiovascular risk in healthy populations,2,3 which appears to be even more pronounced among patients with type 2 diabetes.4,5 While there is clear evidence that heavy alcohol intake is positively associated with hypertension,6,7 the association of moderate alcohol intake and BP remains unclear in observational studies. Some studies suggest a trend toward higher BP in moderate alcohol consumers, especially men,8–10 while others suggest a beneficial association.11,12 Some short-term

Correspondence: Iris Shai (irish@bgu.ac.il).

Initially submitted February 25, 2015; date of first revision April 12, 2015; accepted for publication July 13, 2015; online publication August 1, 2015.

1Department of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; 2Soroka University Medical Center, Beer-Sheva, Israel; 3Nuclear Research Center Negev, Dimona, Israel; 4Cardiology Division, Hadassah Hebrew University Medical Center, Jerusalem, Israel; 5Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard School of Public Health, Boston, Massachusetts, USA.

*These authors contributed equally to this work.

© American Journal of Hypertension, Ltd 2015. All rights reserved. For Permissions, please email: journals.permissions@oup.com
randomized controlled trials of red wine consumption did not report significant effects on BP among hypertensive or normotensive participants\textsuperscript{13,14} or in patients with type 2 diabetes.\textsuperscript{15} Yet, a recent clinical trial found beneficial effects of red wine polyphenols on BP.\textsuperscript{16} Alcohol consumption patterns, as well as the timing of BP measurements, likely modulate the observed associations between alcohol consumption and BP.\textsuperscript{17}

Most of the available studies are based on office BP readings, which can be affected by variable measuring techniques, the “white coat effect,” and the diurnal variability of BP. Short-term studies using ambulatory BP monitoring (ABPM) show no significant effect of moderate alcohol consumption on the average 24-h BP, but suggest a reduction in BP several hours after alcohol intake (apparently due to its direct vasodilatory effect) in 1 study\textsuperscript{18} and higher values of systolic and diastolic BP during the morning and during waking hours among moderate and heavy alcohol drinkers in another study.\textsuperscript{19}

In humans, ethanol is oxidized to acetaldehyde, mainly (~70%) via hepatic class I alcohol dehydrogenase (ADH1B).\textsuperscript{20,21} A common genetic variant of its beta polypeptide, ADH1B rs1229984, encodes an amino acid substitution from Arg to His at position 48 (Arg48His), greatly enhancing the enzyme’s reaction rate.\textsuperscript{21,22} Observational studies suggest that the slow metabolizing variant is associated with elevated BP in the Japanese population\textsuperscript{23} compared to fast metabolizers (ALDH*2*2), but such an association was not observed in a Caucasian population.\textsuperscript{24}

In our preparatory 3-month randomized controlled trial of wine consumption in patients with type 2 diabetes,\textsuperscript{15} we did not detect a red wine-mediated effect on office BP measurements. Hence, here we evaluate the effect of 6 months of moderate red wine consumption on BP dynamics by ABPM in type 2 diabetic, alcohol abstainers. This allows specific detection of more transient BP effects after wine consumption, substantiating our analysis of safety issues. Furthermore, given the high prevalence and impact on enzyme activity of the rs1229984 polymorphism of ADH1B, the effect of this polymorphism on ABPM was assessed.

\section*{Methods}

This trial is a predefined sub-study of the 2-year CaArdiOvaSCuLAr Diabetes & Ethanol (CASCADE) randomized clinical trial (ClinicalTrials.gov Identifier: NCT00784433). The large CASCADE study conducted in 2 sites: the Nuclear Research Center Negev, Israel and at Ben-Gurion University-Soroka Medical Center, Israel; 224 type 2 diabetes patients were randomized to mineral water, white wine, or red wine (150 ml/dinner) consumption for 6 months, assigning gradually at dinner over the first weeks and to avoid driving after drinking. All the beverages were provided at no cost during the monthly visits after returning the empty bottles, to facilitate private usage only. The participants in the study met a physician at baseline, after 3 and 6 months, and were treated regardless of the intervention arm to which they were randomized.

In the present analysis, the predefined outcome measure is BP safety, a cardiovascular disease status component. The trial commenced in 1-phase design in June 2010. Inclusion criteria for the CASCADE trial were: (i) age between 40 and 75 years; (ii) diagnosis of type 2 diabetes according to the American Diabetes Association criteria\textsuperscript{25}; (iii) alcohol abstainers (≤1 drink/week); (iv) nonsmokers; (v) clinically stable; and (vi) willingness to drink wine if so assigned by randomization, as part of a Mediterranean diet intervention. Exclusion criteria included: (i) hemoglobin A1c < 6.4% (46 mmol/mol) or >10% (86 mmol/mol); (ii) insulin >2 injections/day or use of an insulin pump; (iii) fasting serum triglyceride ≥400 mg/dl; (iv) serum creatinine >2 mg/dl; (v) liver dysfunction (≥3-fold increase in serum alanine aminotransferase and/or aspartate aminotransferase); (vi) evidence of severe diabetic complications (such as proliferative retinopathy or diabetic nephropathy); (vii) evidence of autonomic neuropathy manifesting as postural hypotension and/or hypoglycemia unawaresness; (viii) use of medications that might interact with moderate alcohol consumption; (ix) presence of active cancer and/or chemotherapy treatment in the last 3 years; (x) presence of a major illness that might require hospitalization; (xi) clinically assessed as having high potential of addictive behavior and/or personal or family history of addiction or alcohol abuse; (xii) women with first degree relatives with breast cancer; (xiii) pregnant or lactating women; and (xiv) participation in another interventional trial.

Based on a systematic review,\textsuperscript{18} the current investigation has been powered to detect a minimal difference of 2.7 mm Hg in the average change of systolic BP between the groups, assuming an SD of 2.5 mm Hg, α = 0.05, and 80% power. The actual differences between the intervention arms were of a larger magnitude. After randomization, the main parameters were evenly distributed between the 2 groups (Table 1). The main study as well as the ABPM sub-study were approved and monitored by the human subjects’ ethics committee of Soroka Medical Center and Ben-Gurion University; the participants received no financial compensation or gifts.

\section*{Intervention}

The participants were instructed to consume 150 ml (5 ounces) of the assigned beverage during dinner for 6 months, using a provided standard 150-ml measuring glass. The randomized groups were: dry red wine (16.9 g alcohol; 14.2% by volume); 270.1 mg gallic acid equivalents (GAE) total phenols; 120 kcal/150 ml) or mineral water (0 g alcohol, 0 kcal). The water group received 18.9 l each month and the wine group received 14 bottles of 325 ml a month. Patients assigned to consume alcohol were instructed to start drinking gradually at dinner over the first weeks and to avoid driving after drinking. All the beverages were provided at no cost during the monthly visits after returning the empty bottles, to facilitate private usage only. The participants in the study met a physician at baseline, after 3 and 6 months, and were treated regardless of the intervention arm to which they were randomized.
All participants received counseling for a Mediterranean diet, without caloric restriction. The monthly dietary guidance was based on quality rather than quantity of foods as meals rich in vegetables and low in red meat and no more than 35% of calories from fat (main source of olive oil and nuts). Wine issues were not discussed at these meetings.

Data collection

Ambulatory blood pressure monitoring (ABPM). We measured 24-h ABPM (Oscar 2 system, SunTech Medical, Morrisville, NC) at baseline and after 6 months of intervention among all 54 participants. The participants were invited to the clinic at their workplace at 9 AM to fit the cuff size by arm circumference and for a detailed explanation about the use of the ABPM, including avoidance of vigorous movements during the increase in cuff pressure, fitting the cuff’s proper position, keeping the cuff dry, and adhering as much as possible to their usual daily routine. In case of shift workers, ABPM was performed only during a morning shift day. The participants were asked to record the time they drank the beverage and the time they went to sleep and woke up on the day of recording. ABPM recorded systolic BP and diastolic BP from the morning it was fitted for the next 24 hours, every 30 minutes during the day (6 AM to 11 PM) and every 60 minutes at night (11 PM to 6 AM). Only ABPM studies with at least 70% of expected measurements were included.

Anthropometric measurements. Participants were weighed without shoes to the nearest 0.1 kg with the use of a wall-mounted stadiometer. Height was measured to the nearest 0.1 cm.

### Table 1. Baseline characteristics of the study population across intervention groups

<table>
<thead>
<tr>
<th>Variables</th>
<th>Assigned intervention group</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Red wine (n = 27)</td>
<td>Water (n = 27)</td>
<td>Entire group (n = 54)</td>
<td></td>
</tr>
<tr>
<td>Age years</td>
<td>56.5 ± 7.2</td>
<td>57.7 ± 5.7</td>
<td>57.1 ± 6.5</td>
<td></td>
</tr>
<tr>
<td>Male sex, no. (%)</td>
<td>25 (92.6)</td>
<td>21 (77.8)</td>
<td>46 (85.2)</td>
<td></td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>30 ± 4.4</td>
<td>28.6 ± 3.6</td>
<td>29.3 ± 4</td>
<td></td>
</tr>
<tr>
<td>Hypertensive (%)</td>
<td>63</td>
<td>59.3</td>
<td>61.1</td>
<td></td>
</tr>
<tr>
<td>HbA1c%, mmol/mol</td>
<td>6.6 ± 0.9, 49</td>
<td>6.9 ± 1.4, 52</td>
<td>6.7 ± 1.1, 50</td>
<td></td>
</tr>
</tbody>
</table>

24-h ambulatory blood pressure

**Systolic**

- Mean 24 h, mm Hg: 130.1 ± 10.9, 128.3 ± 14.6, 129.2 ± 12.8
- Daytime (6 AM to 11 PM) mean, mm Hg: 133.2 ± 11.2, 130.4 ± 14.9, 131.8 ± 13.1
- Nighttime (11 PM to 6 AM) mean, mm Hg: 117.7 ± 12.6, 110.1 ± 35.2, 113.9 ± 26.4

**Diastolic**

- Mean 24 h, mm Hg: 78.6 ± 7.4, 74.6 ± 8.8, 76.6 ± 8.3
- Daytime (6 AM to 11 PM) mean, mm Hg: 81.1 ± 7.5, 76.4 ± 9.1, 78.7 ± 8.6
- Nighttime (11 PM to 6 AM) mean, mm Hg: 68.1 ± 9.4, 61 ± 19.8, 64.5 ± 15.7

**Pulse pressure**

- Mean 24 h mm Hg: 52.2 ± 6.9, 53 ± 9.1, 52.6 ± 8

24-h Blood pressure variability

**Systolic (SD)**: 14 ± 2.4, 13.2 ± 2.7, 13.6 ± 2.6

**Diastolic (SD)**: 11.3 ± 2.4, 10.7 ± 3.4, 11 ± 2.9

Medication use

- Antihypertensive drugs, no. (%): 8 (29.6), 11 (40.7), 19 (35.2)
- No. of antihypertensive drugs: 0.3 ± 0.4, 0.4 ± 0.5, 0.35 ± 0.5
- Lipid-lowering therapy, no. (%): 10 (37), 12 (44.4), 22 (40.7)
- Anti-platelet therapy, no. (%): 7 (25.9), 10 (37), 17 (31.5)
- Oral glycemic-control medications, no. (%): 13 (48.1), 17 (63), 30 (55.6)
- Insulin treatment, no. (%): 2 (7.4), 0, 2 (3.7)

Data presented as mean ± SD unless otherwise indicated. All differences between groups were insignificant. Abbreviations: BMI, body mass index; HbA1c%, hemoglobin A1c%.

*The average of the differences between the systolic and diastolic blood pressure over 24 hours.
nearest millimeter at baseline for determination of body mass index. Waist circumference was measured halfway between the last rib and the iliac crest. Participants were measured at baseline and at 6 months.

**Genetic analysis of alcohol dehydrogenase**

ADH1B*1 and ADH1B*2 genotyping was determined using a 7300 Real Time PCR system (Applied Biosystems, Foster City, CA) using AccuStart Genotyping ToughMix Rox (Biosearch Technologies, Novato, CA) and designated primers for the specific single nucleotide polymorphism according to the manufacturer’s protocol.

**Statistical analysis**

For intention-to-treat analyses, we included all 54 participants. The primary outcome was the 24-h BP changes from baseline between the assigned groups, as assessed by ABPM. We calculated mean BP measurements from all 24-h readings and separately for day (6 AM to 11 PM) and night time (11 PM to 6 AM), as well as means from the values at each hour. The delta between means of 6 months to baseline was analyzed without imputation of missing data. Nonparametric test analyses were performed as the BP parameters were not normally distributed and the sample size was small; we assessed the within-person changes from baseline in each beverage group by Wilcoxon test and compared the effect between groups by Mann–Whitney test. Stratification by hemoglobin A1c% groups, body mass index groups, and use of antihypertensive groups was used for sensitivity analysis. The tests were 2-sided, performed on SPSS software, version 20.

**RESULTS**

The overall retention rate was 92% after 6 months of intervention (Supplementary Appendix 1). Four participants dropped out during the study; 1 withdrew from the mineral water intervention group (lack of motivation) and 3 from the wine group (2 were unable to drink wine and 1 lacked motivation). According to data from the food frequency questionnaire, the adherence to daily consumption of the supplied beverages was 76.0% in the wine group and 80.9% in the water group (P = 0.71 between groups). The baseline characteristics of the participants are shown in Table 1. The 2 study groups demonstrated similar distribution. The average age was 57 years, 85% were men with a mean body mass index of 29.2 ± 4 kg/m², and mean hemoglobin A1c 6.7 ± 1.1% (50 mmol/mol). Hypertension was diagnosed in 61% of the participants and 35% were on chronic antihypertensive therapy (average number of antihypertensive medications was 1.5 among consumers); no significant changes were found between groups and compared to baseline measurement. Mean baseline 24-h ABPM was 129/77 mm Hg and mean pulse pressure was 52.6 ± 8 mm Hg. Mean baseline intake of alcohol was 2.6 g/day or about 1 drink per week. The baseline 24-h ABPM (Figure 1) did not reveal a substantial difference of BP levels between day and night among the type 2 diabetes participants, though such difference would be expected in non-type 2 diabetes population.

After 6 months of intervention the participants achieved a minor weight loss of −1.3 kg ± 3.7, similarly between groups, those changes were not correlated with systolic or diastolic BP changes. Six-month differences in mean 24-h BP were negligible (systolic: −2.1 mm Hg in the wine group vs. −2.0 mm Hg in the mineral water group (P = 0.66; confidence interval (CI): −3.8 to 3.7); diastolic: +0.5 mm Hg in wine group vs. −0.6 mm Hg in the water group (P = 0.71; CI: −2.7 to 3.8)), as well as minor differences in mean daytime or nighttime and mean 24-h changes in pulse pressure (−0.3 mm Hg in the wine group vs. −0.6 mm Hg in the water group (P = 0.9; CI: −1.1 to 1.4)). However, when comparing the 6-month changes between the individual hours across the 24-h trajectory (Figure 2a–c), reductions in BP were observed in the red wine group at midnight (3–4 hours after ingestion): systolic: red wine: −10.6 mm Hg vs. mineral water: +2.3 mm Hg (P = 0.03; CI: −14.1 to −0.6), diastolic: red wine: −7.7 mm Hg vs. mineral water: +0.7 mm Hg (P = 0.076; CI:

![Figure 1. Baseline average systolic and diastolic ambulatory blood pressure monitoring over 24 hours of the red wine and mineral water groups. Red wine (n = 27), mineral water (n = 27). Black (wine group) and white (water group) points present means of ABPM in each hour.](image-url)
−11.8 to 0.9); and at 7–9 AM: systolic: red wine: −6.2 mm Hg vs. mineral water: +5.6 mm Hg (P = 0.014; CI: −17.3 to −0.8). These effects were accordingly reflected in a pulse pressure reduction (Figure 2c) in the early morning hours (red wine: −4.2 mm Hg vs. mineral water: +1.8 mm Hg (P = 0.032; CI: −9.9 to −0.2)) and a trend toward a
Supplementary Appendix 3

The association between alcohol and ADH1B genetic variants is presented in Figure 3. Among those assigned to the wine group, participants who were homozygous for the gene variant encoding fast ethanol metabolism, ADH1B*2 (TT), had a significant decrease in mean 24-h systolic BP (−8 vs. +3.7 mm Hg (P = 0.002; CI: −5.7 to −3.2)) and pulse pressure (−3.8 vs. +1.2 mm Hg (P = 0.032; CI: −9.8 to −0.20)) as compared to the non-fast metabolizers (i.e., those either homozygote to the slow, wild-type, ethanol metabolism variant, or heterozygotes). Nonsignificant differences were found in the polymorphisms groups through beverages intervention. Moreover, no genetic association was observed for the water group in the different polymorphisms (Supplementary Appendix 2).

DISCUSSION

We found that the daily consumption of moderate wine intake (150 mL of red wine, equivalent to approximately 17 g alcohol) within an interventional randomized control trial setting does not affect 24-h BP, with potential hints toward a transient hypotensive response at specific time intervals. We also found a differential association of wine and BP between fast and slow ethanol metabolizers, as defined by a common ADH1B variant. Amongst fast alcohol metabolizers we found a significant reduction of average 24-h BP, which was not apparent among the slow metabolizers.

Our trial has several limitations, including being a subgroup analysis with a relatively small sample size, particularly in the genetic analysis, and the under-representation of women (reflecting their proportion in this specific work-place). Thus, our results should not be interpreted as strong evidence of a wine effect, and can only be used to inspire hypotheses that require further verification. Although only participants recruited from the Nuclear Research Center Negev were recruited to this sub-study, we did not find significant clinical or demographic differences between this sub-group and the entire CASCADE study group, other than the smaller proportion of women. Second, although the retention rate of the participants was high, as assessed by their monthly attendance to follow-up visits, return of empty bottles, and questionnaires (data not shown), blood or urine levels of alcohol or its metabolites were not available.

The strengths of the study include the enrollment of alcohol abstainers in a 1-phase study design (in which all participants started the intervention simultaneously), and the relatively long duration of intervention compared to previous randomized alcohol studies. The fact that all the participants work in the same workplace under similar conditions, and commute to work by the same transport at identical times, provided a relatively uniform background to the study in both groups and minimized confounding effects that could be introduced by variable waking hours activity and work place conditions.

After 6 months of intervention we did not find a wine effect on mean 24-h BP in the entire group. Previous studies showed a decrease in BP approximately 4 hours after alcohol consumption.18 We also found evidence for such BP-lowering effect in our study without long-term effects on mean BP throughout the day. We also did not observe an elevation in systolic BP 10–15 hours after alcohol ingestion, as was described in a previous study.18 On the contrary, we demonstrated that wine intervention modestly restrained increasing BP in the morning that is often seen in ABPM.27,28 This discrepancy between our and previous studies may reflect differences between short-term and long-term alcohol consumption, difference in the populations studied, and/or the background Mediterranean diet. Whether the transient decrease in BP around midnight and in the early morning hours would translate to a long-term clinical benefit remains to be determined. The analysis with resolution to an hour or other time interval was of an exploratory nature and suggests that the wine effect is plausible, without need for further multiple comparisons.

Modest reductions in mean 24-h systolic BP were found in a sub-group, post hoc analysis, in participants homozygote to the ADH1B*2 (TT) gene variant encoding for fast ethanol metabolism. Some observational studies have shown that alcohol consumers who are slow ethanol metabolizers (genotype CC) had a higher risk of hypertension than fast ethanol metabolizers (genotype CT or TT)24,29 and had higher levels of office BP,30 while other studies found no difference between the genotypes.31,32 Although the results of our post hoc analysis cannot be taken as definite proof of a genetic interaction and should only be regarded as hypothesis generating, some support to our findings can be found in a recent study of Mendelian randomization analysis based on individual participant data of 261,991 individuals of European descent from 56 studies showed that individuals with the A-allele of the ADH1B rs1229984 gene (“fast metabolizers”),
who also consumed less alcohol, had lower mean systolic BP. However, the explanation proposed in that study was that the gene likely exerts its influence through increased propensity to drink alcohol, expressed by greater quantity of alcohol consumption among individuals with the ALDH *1*1 (wild-type) genotype, compared to ALDH*2*2 genotype. Such factors are eliminated in a randomized intervention study design. The fact that fast ethanol metabolizers had a greater reduction in systolic BP suggests that ethanol itself may have little effect on BP, and the fast degradation to one of its metabolites may cause the hypotensive effect. One possible candidate is acetaldehyde, which has been shown to cause vasodilation and thus to reduce BP in experimental settings.

Our dry red wine (from “Golan Heights” winery) included 14.2% ethanol by volume and ≃270 mg gallic acid equivalents (GAE) total phenols. As red wine is the main alcoholic beverage source of total phenols and, in particular, of resveratrol, we assume that those wine phenols had collateral effects on BP. However, we could not dissect the specific effect of each red wine component.

While it has been hypothesized that the phenolic compound content of wine also contributes to its BP-lowering effect, the neutral effect of wine in slow metabolizers does not particularly support this possibility but does not eliminate it completely. Observational studies, which found BP-raising effects of moderate alcohol consumption, described no relationship to the phenol content in the alcoholic beverages; while other observational studies found a beneficial effect of red wine on BP. We cannot exclude the possibility that in slow alcohol metabolizers the phenols in red wine have the potential to counter-balance a BP-raising effect of ethanol. Furthermore, the hypotensive effect 3–4 hours post-ingestion might be caused by rapid metabolism of ethanol that unmasks the favorable effect of polyphenol activity.

In summary, our findings suggest that moderate consumption of red wine exerts no discernable effect on the mean daily BP in the entire group, though hints for a potential hypotensive effect at specific time intervals. These effects appear to be prominent in diabetic patients who are homozygous for the fast ethanol metabolizing variant, in whom BP parameters are significantly reduced. Whether similar effects also occur in nondiabetic hypertensive patients remains to be evaluated. It is also pertinent to evaluate other metabolic effects of ethanol, which may show differential effects in relation to the rate of ethanol metabolism.

**SUPPLEMENTARY MATERIAL**

Supplementary materials are available at American Journal of Hypertension (http://ajh.oxfordjournals.org).

**ACKNOWLEDGMENTS**

We thank the participants in the CASCADE randomized controlled trial for their consistent cooperation. We deeply thank Harel Segal for his significant contribution. We thank the “Golan Heights” winery and the “Mey-Eden” mineral water company for providing the beverages to the study participants. These companies were not involved in any stage of the design, conduct, or analysis of the study and had no access to the study results before publication. We thank the consultants and health care providers: Drs Arie Moran and Amos Katz from Ben-Gurion University of the Negev, Israel; Dr Tatiana Shuster, Sagit Kachlon, Malka Kaminsky, Yasin Asuly, Tamara Lipovski, and Roman Tsirkin from the Soroka University Medical Center, Israel; Eyal Goshen, Meir Aviv, Hassia Krakauer, Haim Strasler, Drs Ziva Schwartz, Einat Sheiner, and Dov Brickner, Rachel Marko, Esther Katorza, Ilanit Asulin, and Tzvika Tzur from the Nuclear Research Center Negev, Israel; and Drs Eran Leitersdorf and Shai Blag from Hadassah Hebrew University Medical Center, Israel.

The work was funded by a grant from the European Foundation for the Study of Diabetes (EFSD) of the European Association for the Study of Diabetes (EASD).

The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

**DISCLOSURE**

The authors declared no conflict of interest.

All the 3 conditions below were met by all authors:

1. Substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data.
2. Drafting the article or revising it critically for important intellectual content.
3. Final approval of the version to be published.

**REFERENCES**


